New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
17:16 EDTDLR, PXD, CNO, TMO, MNK, QCOR, DTV, GM, AAL, FCX, DG, CIE, HSH, AGN, HES, CBS, VOD, FDO, SHPG, COVPaulson & Co gives quarterly update on stakes
NEW STAKES: Allergan (AGN), DIRECTV (DTV), Covidien (COV), Hillshire Brands (HSH), and Questcor (QCOR). INCREASED STAKES: Shire (SHPG), Cobalt (CIE), Mallinckrodt (MNK), Family Dollar (FDO), and Dollar General (DG). DECREASED STAKES: Thermo Fisher (TMO), Vodafone (VOD), Freeport-McMoRan (FCX), CNO Financial (CNO), and CBS (CBS). LIQUIDATED STAKES: American Airlines (AAL), Pioneer Natural Resources (PXD), Hess (HES), General Motors (GM), and Digital Realty Trust (DLR).
News For AGN;DTV;COV;HSH;QCOR;SHPG;CIE;MNK;FDO;DG;TMO;VOD;FCX;CNO;CBS;AAL;PXD;HES;GM;DLR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
March 17, 2015
09:34 EDTAALActive equity options trading on open
Subscribe for More Information
09:25 EDTAALOn The Fly: Pre-market Movers
Subscribe for More Information
09:13 EDTAGNActavis says Allergan CEO not joining combined company board
Subscribe for More Information
08:58 EDTAGNActavis sees double digit accretion to adjusted EPS within first 12 months
08:58 EDTAGNActavis says will 'immediately begin implementing' integration plans
Subscribe for More Information
08:57 EDTAGNActavis completes acquisition of Allergan
Actavis plc (ACT) announced that it has completed the acquisition of Allergan (AGN) in a cash and equity transaction valued at approximately $70.5B. The combination creates one of the world’s top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23B anticipated in 2015. Actavis continues to expect the transaction to generate double-digit accretion to non-GAAP earnings within the first 12 months, including approximately $1.8B in operating and financial synergies to be realized within one year following the close. These synergies exclude any additional revenue or manufacturing synergies, and are in addition to the $475M of annual savings previously announced by Allergan in connection with Project Endurance. Actavis further expects to generate strong operating cash flow in excess of $8B in 2016, which would enable the company to rapidly de-lever the balance sheet.
08:56 EDTAGNActavis completes Allergan acquisition valued at $70.5B
Subscribe for More Information
08:05 EDTGMGeneral Motors coverage resumed with an Underweight at Morgan Stanley
Morgan Stanley reinstated General Motors with an Underweight and $28 price target. The firm believes GM's agreement to accelerate capital returns to investors is a popular short-term decision but raises questions longer-term by increasing both financial and strategic risks.
07:25 EDTTMOSenate Finance Committee to hold a hearing
The Committee holds a hearing entitled, "Building a Competitive U.S. International Tax System" with Vice President of Tax at Thermo Fisher Scientific, Anthony Smith, on March 17 at 10 am. Webcast Link
06:23 EDTGMGM employees to be deposed for class action case, NY Times says
Subscribe for More Information
March 16, 2015
19:00 EDTAALOn The Fly: After Hours Movers
Subscribe for More Information
18:38 EDTAAL, AGNAmerican Airlines to replace Allergan in S&P 500 as of 3/20 close
Subscribe for More Information
17:24 EDTAALAmerican Airlines up 4% after being added to S&P 500
Subscribe for More Information
17:19 EDTAGN, AALAmerican Airlines to replace Allergan in S&P 500 as of 3/20 close
17:07 EDTFCXCredit Suisse to pay Freeport McMoRan $10M to settle allegations, WSJ says
Subscribe for More Information
11:06 EDTGMGM ignition switch death claims rises to 67, WSJ says
Subscribe for More Information
10:22 EDTAGNEuropean Commission clears Actavis' pending acquisition of Allergan
Subscribe for More Information
10:14 EDTAGNOptions with decreasing implied volatility
Options with decreasing implied volatility: EXPR ULTA SGMS QIHU BKS PAY URBN AGN AGNC
07:39 EDTCBSViacom shareholder meeting may question Viacom, CBS control, NY Post says
Subscribe for More Information
07:37 EDTVODVodafone outlook still positive, says JPMorgan
JPMorgan says that euro weakness and uncertainties relating to the Indian spectrum auction have caused Vodafone's stock to underperform. But the firm believes that, in April, attention should shift to Vodafone's full-year results and its improving outlook in Europe while the company should resume growing in 2H15. The firm keeps an Overweight rating on the shares.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use